Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C43H66O15 |
| Molecular Weight | 822.9751 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 21 / 21 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]4CC[C@@]5(C)[C@]([H])(CC[C@]6([H])[C@]5([H])C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4
InChI
InChIKey=HWKJSYYYURVNQU-DXJNJSHLSA-N
InChI=1S/C43H66O15/c1-20-38(49)32(55-23(4)44)18-37(52-20)58-40-22(3)54-36(17-31(40)46)57-39-21(2)53-35(16-30(39)45)56-26-9-11-41(5)25(14-26)7-8-28-29(41)15-33(47)42(6)27(10-12-43(28,42)50)24-13-34(48)51-19-24/h13,20-22,25-33,35-40,45-47,49-50H,7-12,14-19H2,1-6H3/t20-,21-,22-,25-,26+,27-,28-,29+,30+,31+,32+,33-,35+,36+,37+,38-,39-,40-,41+,42+,43+/m1/s1
Approval Year
Sample Use Guides
For rapid digitalization in 2-3 days, the initial dose was 1.2 to 2.6mg (average 1.96mg). For medium-fast digitalization in 4 days, the loading dose was 2.0 to 3.2mg (average 2.7mg). For slow digitalization 0.1 to 0.4mg was required for 5 to 6 days without loading dose. The maintenance dose was 0.1 to 0.4mg (average 0.33mg) daily.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QC01AA52
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
||
|
WHO-ATC |
C01AA02
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
||
|
WHO-VATC |
QC01AA02
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
||
|
WHO-ATC |
C01AA52
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Q28IFH7A50
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
PRIMARY | |||
|
DB13691
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
PRIMARY | |||
|
SUB12718MIG
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
PRIMARY | |||
|
5511-98-8
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
PRIMARY | |||
|
226-855-1
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
PRIMARY | |||
|
68
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
PRIMARY | |||
|
199
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
PRIMARY | |||
|
11765960
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
PRIMARY | |||
|
SUB22301
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
ALTERNATIVE | |||
|
100000086013
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
PRIMARY | |||
|
DTXSID00203630
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
PRIMARY | |||
|
α-Acetyldigoxin
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
PRIMARY | |||
|
m4456
Created by
admin on Sat Dec 16 01:49:50 UTC 2023 , Edited by admin on Sat Dec 16 01:49:50 UTC 2023
|
PRIMARY | Merck Index |
SUBSTANCE RECORD
